Search

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and honors, given by the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH) organizations.

… Monday, June 22, 2020 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and honors to our staff, given by the American Association for Cancer Research (AACR) , the American Society of Clinical Oncology (ASCO) , and the American Society of Hematology (ASH) organizations: American

Clinically meaningful secondary cancer occurred in non-small cell lung cancer survivors, both within and beyond the thorax and over a prolonged period, according to a new study by a multidisciplinary team of lung cancer experts at MSK. The findings underscore the importance of risk-adapted, symptom-responsive survivorship care that includes evaluating heritable risk.

… Thursday, January 22, 2026 Clinically meaningful secondary cancer occurred in non-small cell lung cancer (NSCLC) survivors, both within and beyond the thorax and over a prolonged period, according to a new study by a multidisciplinary team of lung cancer experts at Memorial Sloan Kettering Cancer Center

MSK researchers presented exciting advances in medical oncology for a range of cancer types at the ESMO Congress 2025. Highlights included the latest updates on three phase 1 trials testing innovative treatment approaches for select patients with advanced solid tumors, NSCLC, and pancreatic cancer. MSK researchers also presented new insights about mismatch repair deficient solid tumors that may inform tailoring personalized treatments.

… Monday, October 20, 2025 Memorial Sloan Kettering Cancer Center (MSK) researchers presented exciting advances in medical oncology for a range of cancer types at the European Society for Medical Oncology Congress 2025 held October 17 to 21 in Berlin, Germany. Highlights included the latest updates on

In a study of patient tumor samples, researchers have found common mutations in parts of the genome that control gene regulation.

… Thursday, November 13, 2014 Summary In a study of patient tumor samples, researchers have found common mutations in parts of the genome that control gene regulation. About three billion base pairs make up the human genome. But less than 2 percent of that material contains the sequences for genes that

Results from a phase 2 clinical trial report a combination of two checkpoint inhibitor immunotherapy drugs given before melanoma surgery prevents this aggressive skin cancer from coming back. This new drug combination also has fewer side effects than other immunotherapy treatments.

… Wednesday, October 26, 2022 When Nancy Schroeder found out her melanoma had spread to her lymph nodes four years after she’d had surgery from a local dermatologist near her home in Florida, she knew she needed to go to Memorial Sloan Kettering Cancer Center (MSK) to benefit from the latest research and

Newly published results from a randomized, Phase III trial show that the drug sunitinib malate (Sutent®) is more effective than the conventional treatment given as an initial therapy for patients with advanced kidney cancer.

… Wednesday, January 10, 2007 Newly published results from a randomized, Phase III trial show that the drug sunitinib malate (Sutent ® ) is more effective than the conventional treatment given as an initial therapy for patients with advanced kidney cancer . The multicenter study, led by Robert Motzer,

In partnership with the Nassau County Department of Health, MSK Nassau will help equitably distribute COVID-19 vaccinations.

… Wednesday, March 10, 2021 As part of MSK’s commitment to support equitable access to COVID-19 vaccines , MSK has partnered with the Nassau County Department of Health to distribute vaccinations to residents from communities disproportionately impacted by the pandemic. The partnership was announced today

Memorial Sloan Kettering Cancer Center (MSK) has joined the COVID-19 Technology Access Framework, a multi-site effort aimed at accelerating the production of essential health-related technologies that will help prevent, diagnose, and treat infections during the COVID-19 pandemic.

… Wednesday, April 29, 2020 Memorial Sloan Kettering Cancer Center (MSK) has joined the COVID-19 Technology Access Framework , a multi-site effort aimed at accelerating the production of essential health-related technologies that will help prevent, diagnose, and treat infections during the COVID-19 pandemic

Incorporating radiomics with methyl guanine methyl transferase (MGMT) status can more accurately stratify glioblastoma patients into groups with different survival risks compared to using either prediction tool in isolation.

… Thursday, April 4, 2019 Incorporating radiomics with methyl guanine methyl transferase ( MGMT) status can more accurately stratify glioblastoma patients into groups with different survival risks compared to using either prediction tool in isolation, according to the results of our retrospective research

An innovative 3D motion management platform for guiding stereotactic body radiation therapy (SBRT) significantly reduced late urinary toxicity in patients treated for prostate cancer compared to a commercial image-guidance system, according to study results presented October 2 at the ASTRO 2023 Annual Meeting in San Diego.

… Wednesday, October 11, 2023 An innovative 3D motion management platform for guiding stereotactic body radiation therapy (SBRT) significantly reduced late urinary toxicity in patients treated for prostate cancer compared to a commercial image-guidance system, according to  study results presented October